List of Antibodies Companies with Phase 2 Active Clinical Trial - 221

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation. This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease. It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Abcentra is developing a potential solution for patients with cardiovascular inflammation – therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease. Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline). Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors. Several additional indications are also being pursued. Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai. Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

Privately-held Montreal-based biotechnology company Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. Currently having one clinical-stage program with phase I data. Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology. Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline. Established strategic partnerships to access mAb generation, humanization, antibody-drug conjugates, and CHO production technologies

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.

AltruBio is developing first-in-class immunomodulators to target diseases of the immune system. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.

Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.

Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.

Aptarion is dedicated to leveraging the strengths of biostable L-aptamers (highly specific "chemical antibodies") across the biomedical spectrum. Besides the discovery of new L-aptamers for the functionalization of sensors with its powerful platform technology, Aptarion pursues the development of its proprietary existing L-aptamers as therapeutics in areas of high medical need.

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

Aptitude Vision is a biotechnology company that specializes in developing next-generation synthetic biomolecules for treating vision-threatening diseases by simultaneously targeting multiple pathological processes.

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Aurigene Pharmaceutical Services is leading contract research, development, and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery and development our mission is to relentlessly work for the success of our clients and to build long term relationships through a holistic approach to accelerate the journey of a molecule from laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and ultimately patients. We offer integrated and standalone services for medicinal chemistry, biology, preclinical services, DMPK studies, development and manufacturing for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.

Avalo Therapeutics Inc. (Name changed from Cerecor Inc.) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"​). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets"​) from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

BioAtla is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics™ (CAB) are designed to target and treat cancer with greater precision and fewer side effects.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

OUR COMPANY BioMed Valley Discoveries, Inc., is a clinical stage biotechnology company with a mission to address unmet patient needs across a wide spectrum of diseases. Operating since 2007, BioMed Valley Discoveries advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, our stable long-term funding allows us to advance programs that may not fit within the model of more traditional clinical development groups. OUR APPROACH BioMed Valley Discoveries leverage several hundred experts at leading academic and clinical institutions to move projects forward in the early stages of clinical development. Our partners have a proven track record of scientific rigor and experience in efficient study execution. Our selection of development partners is based on our desire to address unmet patient needs and achieve critical development milestones as swiftly as possible. Through this approach, we endeavor to quickly answer scientific questions and determine next steps in the development process. OUR TEAM BioMed Valley Discoveries calls on the talents of a core leadership team of scientists who are focused, passionate, and committed to advancing new medical innovations to improve the lives of patients with difficult-to-treat diseases. Our team brings extensive experience from pharma, biotech, and academia. By utilizing unique advantages from each of these settings, BioMed Valley Discoveries creates a highly creative and functional drug development environment. We take a nimble and thoughtful approach to advancing programs with a focused sense of urgency, allowing for the most efficient path forward.

BiOneCure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative ADC drugs for the treatment of cancers. The company was founded in 2017 by a group of industry veterans who have worked in global biopharmaceutical companies. Their research focuses on creating innovative technology platforms and adopting a multifaceted approach to develop new medicines that exceed current standards. The current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs, aiming to be the first-in-class or the best-in-class products.

BioNova Pharmaceuticals Ltd is an innovative biotech company engaged primarily in the discovery, development and commercialization of breakthrough therapies for the treatment of diseases with high unmet medical need, with a focus on the Greater China market Our talent, scientific knowledge and research capabilities help us accelerate drug development in China and bring innovative medicines to the Chinese patients

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support four marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have over 1,300 employees worldwide dedicated to building a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery.

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. is a clinical-stage biotech company dedicated to the discovery, development, and commercialization of anti-tumor biotherapeutics. With the core value of 'Together, We Improve Human Health,' the company focuses on multi-level collaborations and developments to advance its mission.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

CatalYm is a Germany-based biotechnology company that researches and develops gene therapies for the treatment of cancer.

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company’s preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

About Chembio Diagnostics: Chembio is a leading point-of-care diagnostics company focused on creating fast actionable tests to diagnose diseases quickly and accurately, including STIs and COVID-19, enabling expedited treatment. Chembio tests are easy to use and provide results in approximately 15 minutes using some of the smallest sample sizes of fingertip blood, nasal swabs and other sample types. Chembio recently received FDA CLIA Waiver for the first rapid point-of-care combination test for HIV & Syphilis. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com. About the DPP Rapid Test Platform: Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Cullinan Oncology is advancing a growing portfolio of innovative, early-stage clinical therapeutic assets by capitalizing on the latest scientific breakthroughs. We combine a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative oncology drugs.

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway, being investigated in a Phase 1a/1b trial in patients with solid tumors. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at www.curis.com.

Receiving blood is receiving life. DIAGAST's goal is to help healthcare professionals transmit life with the help of the best blood group determination technologies. Even though it is not always a matter of life and death, transfusion errors are never acceptable. Over the last 30 years, DIAGAST has developed unparalleled expertise and know-how in the transfusion sector. DIAGAST develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST also ensures the research, manufacturing and marketing of all its products. Moreover, DIAGAST offers a wide range of related services, such as a training center for their automated systems, a hotline and on-site follow-up on automaton calibration. We even make control and measurement tools available over the Internet. DIAGAST is now the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions.

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.

Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com. To view our community guidelines, click here: https://bit.ly/3BYPnpK

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them.

Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage. Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.

Eutilex is a KOSDAQ listed company that researches and develops new drugs with a focus on immunotherapy

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage prostate cancer and multiple myeloma. FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

Genome & Company is a global pharmaceutical bio company that focuses on research and development of microbiome medicines and new drug targets ('targets')-based immunotherapy agents based on abundant clinical data and multi-omics technology (Multi-Omics). Since its establishment in 2015, Genome & Company has been a global leader in the field of microbiome immuno-oncology drugs and new target immuno-oncology drugs, implementing the 'Bed-to-Bench' strategy (clinical data-based research) of GNOCLE™, an independent drug candidate discovery platform. Development Strategy), we have collaborated with major domestic and foreign pharmaceutical and bio companies and research-oriented hospitals. In the future, Genome & Company will not only accelerate the development of innovative treatments for high unmet medical needs by utilizing the microbiome and new drug targets, but will also strengthen its production and commercialization capabilities to become a fully integrated pharmaceutical bio company.

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers.

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.

GV20 Therapeutics (https://gv20tx.com) was incorporated in 2016 with sites in Cambridge, USA, and Shanghai, China. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.

弊社は、バイオ革命によって急速に発展し始めている再生医療分野において、体性幹細胞再生医薬品/iPSC再生医薬品の研究開発を行っているバイオベンチャーです。2015年6月には東証マザーズに上場。再生・細胞医薬品の開発・製造を世界で先駆けて取り組み、病で苦しむ患者さんに治療法を提供し希望を届けることを目標としています。 Our company is a bio venture which is doing R & D of somatic stem cell regenerating medicine / iPSC regenerating medicine in the regenerative medicine field which is rapidly developing by the bio-revolution. We were listed on TSE Mothers in June 2015. Our long-term object is to deliver hope to patients suffering from illness by providing treatment methods by pioneering the development and manufacture of regeneration and cellular medicines worldwide.

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease and other serious disorders.

Hope Medicine (HopeMed) is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company was established on the foundation of deep understanding of disease biology and translational medicine, and decades of scientific research in the laboratory of the founder, Professor Rui-Ping Xiao, at Peking University. With a management team of highly accomplished industry veterans combining entrepreneurship and global pharma experience, HopeMed is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations. Strategically, we are building a robust pipeline in the field of endocrine, cardiovascular and metabolic diseases, with a special focus on women’s health, through internal R&D capabilities, access to external technology platforms to enable a variety of molecular modalities, as well as in-license of complementary and differentiated assets to address unmet medical needs.

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.

Clinical-stage Biopharmaceutical Company developing burfiralimab against Chronic hepatitis B and autoimmune diseases. Also Antibodies and small molecules are in the pipeline for oncological and immunological disorders.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 Phase I study was completed in Feb 2019 and its Phase 2 study is being prepared. ImmuneOncia is also developing several antibodies targeting novel immune-checkpoints.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a private, clinical-stage oncology company dedicated to discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1b/2 clinical development for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (a novel bispecific antibody targeting LILRB4 and CD3), and undisclosed immunology and oncology programs. For more information, please visit www.immune-onc.com.

Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. ACCEPTABLE USE POLICY We welcome your comments on our page but we ask that you help us comply with the Therapeutic Goods Advertising Code. Please consider these guidelines before commenting. We will remove any comments that may result in us breaching the Code. We love when you comment and tag your friends and family on our posts but we ask that you do not: • endorse our product if you are: o an employee or contractor of a government authority, a hospital or a healthcare facility o a health practitioner, health professional or medical researcher o involved with the production, sale, supply or marketing of our product o not using your own name on this social media platform • imply that a government authority, a hospital or a healthcare facility endorse our product • make comments about how a product works for you outside of its intended purpose, as these comments can be dangerous or misleading - our products are developed for particular purposes, as stated on the label and/or in our advertising • make comments about serious conditions, diseases, ailments or defects, such as comments about how a product helped with your treatment of a serious disease or how it will relieve a tagged person's serious condition We also have an obligation to make sure any advertisements we make, including endorsements and testimonials, are not misleading. Therefore we promise to disclose: • where a person has been, or will be, compensated for making a testimonial • where we have actors making the testimonial, such as in cases where the original person who made the testimonial does not want to appear in our advertisement • where the person making the testimonial is an immediate family member of anyone employed by our company.

Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.

Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor is in a Phase 1 multiple ascending dose (MAD) study. IMG-008, an in-house developed long-acting anti-IL-36R mAb is entering global Phase 1 clinical development.

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases.

Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.

Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources. In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others. In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”. In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential. In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development.

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. SLP®immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP®lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP®immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases. ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV. The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com SLP® and AMPLIVANT® are registered trademarks in Europe.

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.

Jasper Therapeutics is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases. Their mission is to make a significant difference in the lives of patients suffering from these conditions.

Kira Pharmaceuticals is a clinical-stage, global biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline of nine (9) novel complement assets focused on validated targets across the complement cascade. With an experienced team of complement biology experts, drug developers, protein engineers and leaders from across the pharma and biotech industry, Kira Pharmaceuticals is uniquely positioned to tackle some of the most complex and toughest challenges in the complement space and to deliver first-in-class and best-in-class therapies to transform the lives of patients. The company is headquartered in Cambridge, Massachusetts with offices in Suzhou and Shanghai, China, and Australia.

Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.

LigaChem Biosciences (formerly LegoChem Biosciences, Inc.) is a clinical stage biopharmaceutical company focused on the development of novel therapeutics utilizing its proprietary drug delivery technologies and therapeutic antibodies. The company's pipeline includes antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer and other serious diseases. LigaChem Biosciences is headquartered in Daejeon, South Korea, with additional offices in Seoul. The company has entered into co-development and license agreements for its ADC programs and has completed acquisitions by other companies. LigaChem Biosciences is committed to advancing innovative treatments for patients in need.

LOKON PHARMA is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer-based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Longbio Pharma is founded in 2018, and located in Zhangjiang Hi-tech Park, Shanghai. There are 40+ scientists, 10+years experiences in protein drug development (antibodies and fusion proteins) .The co-founder team successfully developed two drugs for marketing (accumulated global sales USD 30 Billion). Longbio Pharma is focusing on R&D the innovative drugs of autoimmune and rare diseases (allergy and complement).

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best.  The neuroscience market is on a growth trajectory. We see rapidly growing knowledge in the field, with many new exciting advances, expanded drugability as well as increased regulatory approvals. Brain disorders are sharply on the increase and the disease burden is growing. We are one of the only global pharmaceutical companies solely focused on the brain, and our research programs tackle some of the most complex challenges in neuroscience. Our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain disorders. Our ambition is to be #1 in Brain Health in the eyes of the patients we tirelessly serve. We are 5,400 employees in more than 50 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Whether we work in labs, at desks or in the field, we are all tirelessly dedicated to restoring brain health. We build on our Danish heritage, fostering a culture of collaboration, responsibility and respect. Too many people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions.

Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs. Lyvgen’s most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409, a mAb agonist for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGFβ1/2/3, and anti-PD-1 blocking antibody LVGN3616. Lyvgen has initiated Phase I clinical trial of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA. Lyvgen plans to start Phase I testing of LVGN6051 in China, LVGN7409 and LVGN1673 globally. Lyvgen employs over 35 scientists with global pharmaceutical research and development experiences at its research sites in China and the USA.

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. We currently have a pipeline of product candidates in human clinical testing, including seven immuno-oncology programs. Our product candidates and platforms have attracted partnerships with leading pharmaceutical and biotechnology companies around the globe.

Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to address hypertriglyceridemia and other metabolic diseases.

Marengo Therapeutics, a clinical stage biotech company, is pioneering an entirely new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.

MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.

Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression. Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development. For more information, contact info@mediartx.com

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

OUR MISSION: Deliver Innovation. Empower Discovery. Improve Life. For over 25 years, Mirus Bio has pioneered the development of transfection reagents and proprietary technologies for nucleic acid delivery applications. Our work is both technical and cutting-edge, and we promote a culture of creativity, responsibility, and respect. Our team members are engaged and motivated by the desire to support our customers and partners to achieve strong results. Mirus, together with Gamma Biosciences, is establishing the future of science and medicine by developing products that enable product developers within the cell and gene therapy space. As we approach a new era of addressing and conquering life-altering diseases, we will continue to expand our expertise and leadership in transfection to be integral in the future of advanced therapies.

ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and liquid tumors, as well as several of the world’s most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Natick, Massachusetts.

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX's therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials.

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on X @neoimmunetech

Nerviano Medical Sciences S.r.l. (NMS Srl) focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.  NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. Our capabilities are extended by NMS Group affiliates Accelera (AdMet) and NerPharMa (manufacturing), covering the entire drug development process. A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including with encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production. Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets.

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group. Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

Over the past decades, focusing on a battery of conventional genes/proteins involved in the neurodegeneration has been disappointing in the field of neurodegenerative therapeutics. With the scientific responsibility and integrity, Neuracle Science is a clinical stage biotech company specialized in the development of breakthrough therapies for those who are living with serious and devastating neurodegenerative diseases. We provide a foundation for disease-modifying treatments for neurodegenerative diseases, discovering a completely novel and invaluable gene/protein target with unknown significance using non-biased study. Neuracle Science is based in Seoul, South Korea. We were founded in 2015 by scientific leaders in neuroscience, bioinformatics-based drug discovery, GPCR-mediated signaling, and antibody drug.

NeuroTherapia, Inc. is a clinical-stage company developing oral, small molecule therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation. The company was founded in 2015 by the Cleveland Clinic and two of its physician scientists.

NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.

NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases.

Nuvig Therapeutics is a science-driven research and clinical development organization focused on translating novel scientific insights into therapies for patients with chronic autoimmune and inflammatory diseases.

At Ohara, we are aiming to provide not only treatment options for patients, but also aiming to identify and develop innovative tools to improve the quality of diagnosis, prevention and after care in an effort to become a Total Healthcare Solution company for patients.

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers.

OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology.OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.

At OncoVerity, we're not just developing a new treatment—we're doing something truly unique and meaningful. We're establishing a disruptive model using cutting-edge technology to advance cancer therapies. Our mission is to quickly advance therapies that turn hope into reality for patients, their families, and caregivers.   One of the things that sets OncoVerity apart is our approach. We are knocking down traditional barriers between academia and industry by building a team that bridges both worlds. We believe that cutting-edge technology is essential, but it is only one piece of the puzzle.   The true power behind our vision lies in: The brilliance of our people: Your entrepreneurship, ingenuity, drive, and passion are what will fuel our success. The richness of our diversity: A variety of perspectives and backgrounds is essential for groundbreaking solutions. The strength of our collaboration: We are stronger together, and teamwork is at the heart of everything we do.

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to inhibit cancer cell growth while reducing potential harm to healthy cells. We are pursuing trials in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, and Ewing sarcoma. Looking forward, we intend to rapidly broaden our pipeline and invest in the development of our innovative therapies across multiple cancers.

Opsidio is a biotechnology company that develops novel biologic therapeutics for patients suffering from fibrotic and allergic diseases. They are passionate about developing remedies for the millions of people affected by the damaging effects of chronic inflammation.

Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Phanes Therapeutics, Inc. is a biotech company focused on innovative drug discovery and early development in immuno-oncology and eye disease. Our mission is to become a major source of innovation in the biopharma industry. The way we focus on science, the disruptive technologies we develop, and the revolutionary approaches we bring help open up new possibilities in drug discovery. At Phanes, we bring innovation that illuminates the path to cure. Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. One of our therapeutic approaches is to boost both the innate and adaptive immunity with monoclonal antibodies and bispecific antibodies. We are also interrogating non-immune pathways that may play key roles in the tumor microenvironment for their potential in developing novel therapeutics. In addition to a strong pipeline, Phanes has developed disruptive technologies that enable drug discovery. Phanes' three novel technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties. The company has three technology platforms: PACbody™ (for building native IgG-like bispecific antibodies), ATACCbody™ (for building bispecific antibodies with modulated activities) and SPECpair™ (for building bispecific antibodies with enhanced manufacturability). For more information, please visit www.phanesthera.com

PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs. PharmAbcine has its own HuPhage library and innovative selection system. This technology provides therapeutic antibodies for a wide spectrum of indications in oncology, immuno-oncology, ophthalmology, pulmonology etc. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services. PharmAbcine has focused on the development of novel antibody therapeutics since the company’s foundation in 2008 and laid the groundwork for the commercialization of Olinvacimab, PMC-309, PMC-403, and PMC-402. We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s.

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.

At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints. We develop and evolve technologies and instrumentation in collaboration with scientists and researchers around the globe. From simple cloning vectors used to address fundamental questions in biology to bioluminescent assays that help us monitor food safety and water quality, we work side-by-side with our partners in academic, industrial and government institutions to bring the best minds to bear on the toughest questions. Since 1978, we have done this all with a steadfast commitment to sustainable business models that protect our environment, inspire and develop our employees as individuals, support the wellbeing and growth of our communities, and strengthen our relationships with our customers. With 16 branches around the world, Promega products are used by a global community of life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240. *NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. *CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. *IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong, localized immune response within the tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA) 5T4 that is expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. IM1240 has a cleavable capping technology that confines the compound’s therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients.

Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic applications. The company is focused on innovating the way we see and treat cancer, with a particular emphasis on HER-2 cancers. Radiopharm Theranostics has a strong team of executives and board members, and is actively engaged in investor relations and corporate governance. The company has also launched a joint venture with MD Anderson to focus on novel radiopharmaceuticals.

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.

We, at REMD, are a biopharmaceutical company focused on discovering and developing cutting-edge bio-medicines to treat cancer, diabetes and other diseases. REMD develops world class, high quality, and efficient medicine by uniting top American medical scientists and elite Chinese pharmaceutical assets, leveraging the world's most advanced research and development technologies.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.

Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company; all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place.

Discovering and developing novel drugs has been our passion, work and mission for over 50 years. Rottapharm Biotech lives for innovation and innovation lives at Rottapharm Biotech. This is all we are and all we want to be.

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in cancer and other serious diseases.

SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics. Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas. GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

Established and headquartered in Singapore, SCG Cell Therapy Pte Ltd (SCG) is a leading biotechnology company that combines regional advantages in Singapore, China and Germany, to cover the entire value chain from innovative drug research and discovery, manufacturing, clinical development and commercialization. SCG specializes in the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers. SCG collaborates with leading scientists and researchers to bring first-in-class medical products/technologies to enhance innovation in medical product development.

Selecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics. Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, using an innovative platform technology of functional antibody screening and development. We endeavor to improve the survival rate and quality of life of cancer patients by developing anti-cancer immunotherapeutics that selectively stimulate the immune cells. These agents act against tumor cells through the regulation of cytokine function, which plays a key role in the enter cell activities. Based on our technology and expertise in the pharmacology and development field, we aim to provide safe and efficient therapeutics and innovative solutions for next-generation pharmaceuticals.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

Shasqi is a privately held, clinical stage biopharmaceutical company who is focused on bringing the advances of click chemistry to help people fight their cancer. The Click Activated Protodrugs Against Cancer (CAPAC™) Platform is a therapeutic modality based on click chemistry, which utilizes the biocompatible chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected in the desired tumor, which then captures and activates an infused protodrug precisely at the tumor site.

SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.

Skye Bioscience, Inc. is a pharmaceutical company focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially with a focus on modulating the system for the treatment of glaucoma and other diseases. They are developing proprietary cannabinoid derivatives for therapeutic use.

As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process.

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

Starna Therapeutics focuses on extrahepatic targeted delivery technology and is committed to developing innovative drugs with RNA as the core to solve unmet clinical needs. The core team comes from well-known pharmaceutical companies, universities and research institutes. The team has profound capabilities in nucleic acid drug discovery, delivery technology and formulation development.

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology work, including but not limited to, oligo synthesis, gene synthesis, subcloning & PCR cloning, plasmid preparation, mutagenesis, DNA variant libraries, CRISPR sgRNA, protein expression and purification in multiple systems. Relying on our strong DNA sequencing, synthesis, engineering technology platform, and expertise in bioinformatics analysis, we have developed proprietary algorithms to facilitate and expedite the antibody discovery process. Our antibody discovery services include hybridoma sequencing, immune repertoire sequencing, antibody design and production, AI-guided heavy chain and light chain pairing, antibody humanization, affinity maturation, and sdAb.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. Syndax corporate headquarters are in Waltham, MA.

TaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corporate to develop a new generation of oncology molecule. In 2013, TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, we also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidly into various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need. With Taiwan as our home base, we have successfully recruited many experts and consultants in new drug development worldwide. With our extensive experience and expertise in drug development, we can rapidly add value to our product line by moving the progress of our drug products forward. We are committed to our pursuit of high quality and scientific excellence, and establishing global collaboration and partnering. Our goal is to become a global drug development company and deliver new therapeutic hopes for the severe diseases.

Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

Launched in 2005, TechnoPhage is an innovative biopharmaceutical company committed to the R&D of new biological molecules in several therapeutic areas, such as infection, neuroscience, and ophthalmology. TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development, including in-house capacity for process development, and GMP production. The company has recently launched its own GMP manufacturing plant specialized in the production of biologics such as bacteriophages and antibody fragments. TechnoPhage is focused on increasing its pipeline of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across Europe, USA, and Asia. The company’s headquarters are located in Lisbon, in close proximity to the renowned Santa Maria Hospital and the Instituto de Medicina Molecular João Lobo Antunes. Overall, the proximity to these valuable partners ensures the access to the necessary equipment, and to the know-how required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies. TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science.

Tiziana Life Sciences is a dual-listed* (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. *Note: Our market cap for TLSA is likely not accurate because its shares are listed on both the London Stock Exchange and the NASDAQ.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company’s lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company’s lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer’s disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.

Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Cancer immunotherapy Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

Trellis Bioscience is a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant, life-threatening infectious diseases. Antibodies are the immune system's most potent natural weapon against disease. Trellis's innovative proprietary technology CellSpot™ overcomes technical obstacles that have long hindered exploiting the full human antibody repertoire. This ideal source of drugs focuses on the selection of elite antibodies that bind highly conserved target epitopes with high affinity. TRL1068 is a native human monoclonal antibody (for intravenous delivery) whose target is a family of bacterial proteins (DNABII) that play a critical role in maintaining the structural integrity of biofilms by anchoring extracellular bacterial DNA (eDNA) from dead bacteria within the biofilm matrix. TRL1068 binds at high affinity (Kd ~50 pM) to a highly conserved epitope found in nearly all medically significant bacteria, including both Gram-positive and Gram-negative species. High affinity binding to DNABII ensures that the protein is eliminated from the body and thus prevents its deposition elsewhere in the body, where it could form biofilm metastases. Because the bacterial target is only exposed to the antibody after the producing bacterial cell is dead, resistance to this novel intervention is expected to be rare. The FDA granted Fast Track, QIDP (qualified infectious disease product), and Orphan Drug designations for TRL1068.

Trishula Therapeutics is a biopharmaceutical company that focuses on developing cancer therapeutics, including the first-in-class anti-CD39 antibody TTX-030.

Founded in 2016, TrueBinding Inc. is a clinical-stage biotherapeutic company researching and developing first-in-class monoclonal antibody drugs to treat Dementia and Alzheimer's Disease (AD).

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Uniquity Bio is a clinical-stage drug development company dedicated to advancing scientific innovation to deliver novel medicines for patients with immunology and inflammation conditions.

At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases.

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Vega Therapeutics is a clinical stage biotechnology company developing novel, first-in-class therapies for rare blood disorders with overlooked patient needs, starting with von Willebrand disease (VWD). Our lead product candidate, VGA039, is the first purpose-built antibody therapy for VWD with a novel mechanism of action targeting Protein S. By attenuating Protein S cofactor function for tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), VGA039 augments and restores thrombin generation during both initiation and propagation of coagulation, addressing a fundamental mechanism of clot formation in VWD. VGA039 has potential to be a universal hemostatic therapy that can treat various bleeding disorders. Vega is part of a constellation of companies led by Star Therapeutics, a company focused on developing life-changing therapies for people with rare diseases.

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T and bispecific antibodies. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability. XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases. The Company's broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human™ antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company’s product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; Incyte Corporation; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in several indications. Our patented technological platform is built on our expertise in immunology and therapeutics. We develop innovative approaches in immunotherapy with our platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are addressing major therapeutic needs in various domains, including oncology, immunosuppression, viral and bacterial infections. XENOTHERA’s platform allows short-time development thanks to our validated saled-up GMP platform, our in-house bioproduction facility, our clinical experience (400 patients have received GH-pAb today), our mastery of antigens and our regulatory experience. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market, XAB05, a preventive anti- multidrug resistant bacteria GH-pAb, XAV19 an anti-COVID antibody dedicated to patients with moderate disease. XENOTHERA has accumulated preclinical evidence for the therapeutic effect of its oncology GH-pAbs. Two products will be in clinic in oncology in 2023, XON7, its lead pan-cancer targeting solid tumors and LIS22 in peripheral T-Cell lymphoma.

Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families. Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership. We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.

Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively. Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.